The proteomic characterization of the peritumor microenvironment in human hepatocellular carcinoma

Yuhan Gu1, Yuanyuan Guo1,2, Na Gao1

  • 1Institute of Clinical Pharmacology, Zhengzhou University, Zhengzhou, China.

Oncogene
|March 22, 2022
PubMed

Insights

The peritumor microenvironment (PME) differs significantly between hepatocellular carcinoma (HCC) occurrence and progression. Understanding these distinct PME roles in immunity, inflammation, and metabolism could improve cancer diagnostics and therapeutics.

Area of Science:

  • Oncology
  • Proteomics
  • Cancer Biology

Background:

  • The tumor microenvironment (TME) is typically studied in tumor tissue, focusing on progression rather than occurrence, recurrence, or metastasis.
  • The concept of the peritumor microenvironment (PME) was introduced to analyze proteomic changes in liver tissues surrounding hepatocellular carcinoma (HCC).

Purpose of the Study:

  • To conduct a proteomic characterization of the PME in HCC to understand its distinct roles in tumor occurrence and progression.
  • To identify potential therapeutic targets and diagnostic markers based on PME differences.

Main Methods:

  • Proteomic profiling of peritumor liver tissues from HCC patients.
  • Comparative analysis of proteome composition and function between PME for occurrence (PME-O) and PME for progression (PME-P).
  • Validation of identified targets, such as Thymidine phosphorylase (TYMP), in an orthotopic HCC mouse model.

Main Results:

  • The PME for occurrence (PME-O) and progression (PME-P) exhibit distinct proteomic compositions and functions, with minimal overlap in proteins.
  • Immunity is central to PME-O, while inflammation, angiogenesis, and metabolism are critical in PME-P.
  • Proteome profiling identified three distinct PME subtypes associated with different HCC features.
  • Thymidine phosphorylase (TYMP) was validated as an effective antiangiogenic target in an HCC mouse model.

Conclusions:

  • The processes of HCC occurrence and progression are substantially different, driven by distinct PME characteristics.
  • Proteomic insights into the PME offer new avenues for advancing cancer biology, diagnostics, and therapeutics for HCC.
  • Targeting PME components, like TYMP, presents a promising strategy for HCC treatment.